<?xml version="1.0" encoding="UTF-8"?>
<p>A combination of lopinavir and ritonavir has been used to treat COVID-19 because the lopinavir/ritonavir (LPV/r) combination has been confirmed to be effective against SARS-CoV and MERS-CoV [
 <xref rid="B6" ref-type="bibr">6</xref>,
 <xref rid="B66" ref-type="bibr">66</xref>,
 <xref rid="B67" ref-type="bibr">67</xref>]. Another antiviral drug, remdesivir (RDV), was predicted to be efficacious against COVID-19 by target-based virtual ligand screening [
 <xref rid="B68" ref-type="bibr">68</xref>]. RDV is a novel nucleotide analog prodrug that is in development and has demonstrated effective pan-CoV therapy. The first case of SARS-CoV-2 infection in the USA was successfully treated with RDA. Moreover, a randomized, double-blind, parallel-controlled Phase III clinical trial was conducted to recruit SARS-CoV-2-infected patients [
 <xref rid="B4" ref-type="bibr">4</xref>,
 <xref rid="B69" ref-type="bibr">69</xref>].
</p>
